Contact:

Karen Whelan,
Public Relations & Practice Marketing Specialist

Phone: 508-787-1461

Optos to Participate in American Academy of Ophthalmology

09.11.2006

MARLBOROUGH, MA, November 9, 2006 – Optos, a leading medical technology company for the design, development, manufacturing, and marketing of retinal imaging devices, will hold key educational activities at the American Academy of Ophthalmology’s (AAO) Joint Meeting with the Asia Pacific Academy of Ophthalmology (APAO), November 11-14, 2006 in Las Vegas, NV.

Optos will host its Optos Academy meeting on Sunday, November 12th from 6:30 am to 8:00 am. A popular workshop series, the Optos Academy is for Optos Partners and other interested physicians and will highlight techniques and best practices created to enable clinicians to achieve the highest level of success with Optos’ technology. Attendees will also get an update on the technical and clinical components of our newest product, the optomap® fa Dynamic Ultra-Widefield Angiography system, which is designed to offer advanced diagnostic retinal imaging through the provision of widefield angiography. Optos will also provide a sneak-preview of our newest software, Version 2.3, available to Partners shortly after AAO.

In addition, Optos will host nine speaker’s forums titled “Meet the Experts” in its booth, #427, which will highlight various topics such as: “The optomap® fa – New Developments in Dynamic Ultra-Widefield Angiography;” “The Value of the optomap® Retinal Exam to the Anterior Segment Surgeon;” and “Detecting Diabetic Retinal Pathology with optomap® fa Dynamic Ultra-Widefield Angiography versus Conventional Imaging.”

Note to Editors

Optos plc is a leading and rapidly growing medical technology company for the design, development, manufacturing and marketing of devices that image the retina, the light-sensitive area at the back of the eye. Optos' platform technology is the Panoramic200 Scanning Laser Ophthalmoscope device - known as the P200. In a quarter of a second the P200 device produces a high resolution image of up to 200 degrees or approximately 82 percent of the retina in a single capture. The image - branded the optomap® Retinal Exam - provides eye care practitioners with clinically useful information that facilitates the early detection of disorders and diseases evidenced in the retina, such as glaucoma, diabetic retinopathy and age-related macular degeneration.

The Company has recently gained regulatory clearance (CE and FDA 510(k)) to market a second device - P200MA. The P200MA is aimed at the specialist ophthalmic and medical as opposed to the primary care market. It is designed to produce an angiographic retinal image called optomap® fa that supports medical procedures by providing enhanced diagnostic, monitoring and treatment capabilities. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as diabetes, hypertension and certain cancers. Optos’ technology provides an unequalled combination of wide-field retinal imaging, speed and convenience for both practitioner and patient and can help save sight and save lives.

Optos estimates that its P200 device is targeting a recurring US$2 billion market opportunity. Approximately 8.5 million optomap® Retinal Exams have been conducted in the Company’s existing markets, currently the US, Canada, UK and Germany, to date. As at 31 March 2006 Optos had approximately 220 employees serving more than 2,250 customers. Optos plc is headquartered in Dunfermline, Scotland and was admitted to the Main Market of the London Stock Exchange on 15 February 2006 trading under the symbol OPTS.